We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Nanoparticles Loaded with Nitric Oxide Overcome Antibiotic-Resistant Skin Bacteria

By LabMedica International staff writers
Posted on 14 May 2009
A team of drug developers has successfully treated superficial wounds infected with antibiotic-resistant bacteria by using nanoparticles containing nitric oxide.

Nitric oxide (NO) is produced by many cells throughout the body and has several important biologic functions including killing bacteria, healing wounds, and increasing blood flow by dilating blood vessels. More...
Utilizing NO as a therapeutic agent is difficult, however. "The problem is that nitric oxide is very short-lived, and until now, methods to deliver it to targeted tissues in the proper dosages have proven elusive," explained senior author Dr. Joel Friedman, professor of physiology, biophysics, and medicine at Albert Einstein College of Medicine (New York, NY, USA).

To get around this problem, investigators developed a novel type of nanoparticle that could store NO while dry and then slowly release it when exposed to moisture. To test these particles in an animal model, a population of mice suffering from skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) was used. For the study, the MRSA-mice were divided into three groups. One group was treated with the nanoparticles loaded with NO. A second group received nanoparticles lacking nitric oxide, while the third group received no treatment.

Results published in the April 23, 2009, online edition of the Journal of Investigative Dermatology revealed that a week after treatment wounds in the group treated with the NO-containing nanoparticles were significantly improved and smaller than lesions in the two other groups. Bacterial counts were significantly lower in the NO-treated group compared with the other groups, and the NO-treated group showed evidence of accelerated wound healing both visually and microscopically. There were no signs that the nanoparticles were in any way toxic to the animals.

These results encouraged the researchers to conclude that, "NO-releasing nanoparticles have the potential to serve as a novel class of topically applied antimicrobials for the treatment of cutaneous infections and wounds."

Related Links:
Albert Einstein College of Medicine




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.